Dow Chemical Co. v. Viskase Corp.

892 F. Supp. 991, 36 U.S.P.Q. 2d (BNA) 1490, 1995 WL 324559, 1995 U.S. Dist. LEXIS 7269
CourtDistrict Court, N.D. Illinois
DecidedMay 26, 1995
Docket94 CV 6080
StatusPublished
Cited by3 cases

This text of 892 F. Supp. 991 (Dow Chemical Co. v. Viskase Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dow Chemical Co. v. Viskase Corp., 892 F. Supp. 991, 36 U.S.P.Q. 2d (BNA) 1490, 1995 WL 324559, 1995 U.S. Dist. LEXIS 7269 (N.D. Ill. 1995).

Opinion

MEMORANDUM AND ORDER

MORAN, Chief Judge.

The Dow Chemical Company (Dow) brings this action against Viskase Corporation (Vis-kase) seeking a declaratory judgment that seven of Viskase’s patents either are invalid or are not infringed by Dow or its customers. Viskase has moved to dismiss the complaint, arguing that this court lacks subject matter jurisdiction. For the reasons set forth below, the motion is granted.

FACTS 1

Among Dow’s products are various families of ethylene polymers, including the Attane family and several families created using In-site Technology, including the Affinity family. Dow’s customers use these polymers to create assorted end products, including thermoplastic single-layer and multi-layer films used in packaging. At issue here are certain packaging films known as biaxially-stretched shrink films.

Viskase makes and sells its own line of single-layer and multi-layer films formed into bags for the packaging of food. These include biaxially-stretched shrink films. Vis-kase owns seven patents for biaxially-stretched shrink films made from very low density polyethylene (VLDPE). 2 Viskase previously sued Cryovac, one of Dow’s major customers, on five of the seven patents, and that ease was settled out of court. While the terms of the settlement agreement are confidential, Dow believes that the agreement requires Cryovac to disclose any new biaxially-stretched shrink films it produces. Once it does so, Viskase must announce whether it considers such films to infringe on its patents.

In part because of the Cryovac-Viskase litigation, Dow has worked with Cryovac to develop an Insite Technology polymer that both believed could be used to make biaxially-stretched shrink film that would not infringe Viskase’s patents. Dow claims it helped Cryovac so that Dow could recover the sales business it lost as a result of the Cryovac-Viskase lawsuit.

Cryovac made bags from the biaxially-stretched shrink film Dow developed after the Cryovac-Viskase litigation. Dow believes that when those bags were submitted for review under the settlement agreement, Viskase challenged them, claiming that they infringed its patents. 3

*993 American National Can Co. (ANC) is Dow’s other major film-making customer. In 1994 Viskase sued ANC, alleging that ANC infringed the seven patents at issue here by making biaxially-stretehed shrink film using Dow’s Attane polymer. Dow worked with ANC to help ANC produce bi-axially-stretehed shrink film based on its Affinity polymer that does not infringe on Vis-kase’s patents. Viskase has not claimed that the Affinity-based film infringes its patents, but Dow believes (based on the Cryovae suit) that Viskase will do so.

In addition to ANC and Cryovae, Dow has other customers and prospective customers with whom it is working to design polymers which can be used to make biaxially-stretehed shrink film. At least one of those customers has sought Dow’s assistance in avoiding infringement on the Viskase patents and has sought indemnification from Dow against any charge of infrigement made by Viskase.

Based on the above facts, Dow claims that Viskase believes that Cryovae, ANC, and other Dow customers who make biaxially-stretehed shrink films have infringed its patents and intends to enforce its patents against them. Dow also believes that Vis-kase will sue Dow for inducing its customers to infringe the patents. It therefore seeks a declaratory judgment that Viskase’s patents either are invalid or are not infringed by biaxially-stretehed shrink film whose polyethylene component is one of Dow’s Affinity or Insite Technology polymers. Viskase has moved to dismiss Dow’s complaint, arguing that this court lacks subject matter jurisdiction because the complaint raises no case or controversy.

DISCUSSION

The Declaratory Judgment Act (the Act) permits federal courts to “declare the rights and legal obligations of an interested party ‘[i]n a case of actual controversy.’ 28 U.S.C. § 2201. The Act enables a person who is reasonably at legal risk because of an unresolved dispute to obtain judicial resolution of the dispute without having to wait for commencement of litigation by the other side.” Applexion S.A. v. The Amalgamated Sugar Co., No. 95 C 858, 1995 WL 229049, at *3 (N.D.Ill. Apr. 17, 1995).

The Act’s only jurisdictional requirement is that there be an “actual controversy” between the parties. Aetna Life Insurance Co. v. Haworth, 300 U.S. 227, 239-41, 57 S.Ct. 461, 463-64, 81 L.Ed. 617 (1937). The main issue here is what constitutes an actual controversy — specifically, whether a raw materials manufacturer can sue a patentee for declaratory judgment based on the activities of customers who use its raw materials to create potentially infringing products.

The actual controversy test has two core elements: the plaintiff must allege (a) “acts of [the] defendant indicating an intent to enforce its patent” and (b) “present activity which could constitute infringement or concrete steps taken with the intent to conduct such activity.” Arrowhead Industrial Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 737 (Fed.Cir.1988); BP Chemicals Ltd. v. Union Carbide Corp., 4 F.3d 975, 978 (Fed.Cir.1993). The first element depends on the conduct of the patentee; the second refers to the conduct of the asserted infringer. BP Chemicals, 4 F.3d at 978. The parties do not dispute that Viskase has acted to enforce its patents against ANC and Cryovae and that it intends to continue to enforce its patents, nor do they dispute that ANC and Cryovae are engaged in activity that could constitute infringement. But ANC and Cryovae are not the plaintiffs, Dow is. Thus the questions here are whether (a) Viskase’s threats against Dow’s customers and (b) the customers’ filmmaking activities are sufficient to establish an actual controversy between Dow and Viskase.

Dow alleges that Viskase could seek to hold it liable for direct infringement, contributory infringement, or inducing others to infringe. See 35 U.S.C. § 271(a)-(e) (describing the three causes of action for patent infringement). We address each of these causes of action, taking the latter two first.

Contributory infringement “requires that plaintiff establish (1) that defendants sold a material to be used in a patented process; (2) that said material constituted a material part of the patented process; (3) that defen *994 dants knew the material to be especially adapted for use in the infringement of such patent; and (4) that the material did not constitute a staple article suitable for substantial noninfringing use.”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ion Beam Applications S.A. v. Titan Corp.
156 F. Supp. 2d 552 (E.D. Virginia, 2000)
Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. v. Lonza, Ltd.
36 F. Supp. 2d 26 (District of Columbia, 1999)
Minebea Co., Ltd. v. Papst
13 F. Supp. 2d 35 (District of Columbia, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
892 F. Supp. 991, 36 U.S.P.Q. 2d (BNA) 1490, 1995 WL 324559, 1995 U.S. Dist. LEXIS 7269, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dow-chemical-co-v-viskase-corp-ilnd-1995.